Available For Sale Securities Debt Securities Current
Alnylam Pharmaceuticals Available For Sale Securities Debt Securities Current increased by 3.8% to $1.30B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 19.1%, from $1.61B to $1.30B. Over 5 years (FY 2020 to FY 2025), Available For Sale Securities Debt Securities Current shows relatively stable performance with a -1.3% CAGR.
Analysis
How to read this metric
An increase suggests higher liquidity and a conservative cash management strategy, while a decrease may indicate the use of cash for operations or acquisitions.
Detailed definition
This represents the fair value of debt securities held by the company that are classified as available-for-sale and are...
Peer comparison
Commonly reported by large-cap technology firms as 'Short-term investments' or 'Available-for-sale securities'.
current_assets_available_for_sale_securities_debt_securi_87ec82Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.10B | $1.16B | $1.55B | $1.67B | $1.50B | $1.17B | $1.30B | $1.37B | $1.37B | $1.36B | $1.62B | $1.68B | $1.65B | $1.67B | $1.72B | $1.61B | $1.74B | $1.23B | $1.25B | $1.30B |
| QoQ Change | — | +5.4% | +33.3% | +8.1% | -10.1% | -22.3% | +11.0% | +5.8% | -0.0% | -0.7% | +18.5% | +3.9% | -1.9% | +1.6% | +2.9% | -6.7% | +8.6% | -29.2% | +1.4% | +3.8% |
| YoY Change | — | — | — | — | +36.5% | +0.7% | -16.2% | -18.0% | -8.8% | +16.6% | +24.5% | +22.3% | +20.0% | +22.7% | +6.5% | -4.3% | +5.9% | -26.2% | -27.3% | -19.1% |
Available For Sale Securities Debt Securities Current at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's available for sale securities debt securities current?
- Alnylam Pharmaceuticals (ALNY) reported available for sale securities debt securities current of $1.30B in Q1 2026.
- How has Alnylam Pharmaceuticals's available for sale securities debt securities current changed year-over-year?
- Alnylam Pharmaceuticals's available for sale securities debt securities current decreased by 19.1% year-over-year, from $1.61B to $1.30B.
- What is the long-term trend for Alnylam Pharmaceuticals's available for sale securities debt securities current?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's available for sale securities debt securities current has grown at a -1.3% compound annual growth rate (CAGR), from $1.33B to $1.25B.
- What does available for sale securities debt securities current mean?
- The value of short-term debt investments that the company intends to sell within a year.